Standout Papers

Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616 2023 2026 2024100
  1. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616 (2023)
    Christie M. Ballantyne, Puja Banka et al. Journal of the American College of Cardiology

Immediate Impact

63 standout
Sub-graph 1 of 22

Citing Papers

A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis
2024 Standout
Loss of TRIM29 mitigates viral myocarditis by attenuating PERK-driven ER stress response in male mice
2024 Standout
1 intermediate paper

Works of Puja Banka being referenced

Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
2023 Standout
Cardiovascular magnetic resonance techniques and findings in children with myocarditis: a multicenter retrospective study
2015

Author Peers

Author Last Decade Papers Cites
Puja Banka 426 362 229 346 40 711
Edit Nagy 293 446 275 191 30 733
Stella Brili 308 477 271 146 37 651
Gaetano Minzioni 223 480 251 335 49 783
Mitchell Weinberg 296 276 106 209 36 808
M Redonnet 211 360 191 460 55 757
E N Coleman 434 231 187 132 43 671
Naveen Garg 187 333 235 260 54 695
Edgardo Bonacina 160 376 185 307 36 665
Saadeh B. Jureidini 455 312 429 308 53 776
Walter Grosso Marra 179 456 141 231 46 784

All Works

Loading papers...

Rankless by CCL
2026